title: [Role of ovarian suppression in the combined treatment of breast cancer patients in premenopause].
authors.forename: I B
authors.initials: IB
authors.lastname: Shchepotin
authors.forename: A S
authors.initials: AS
authors.lastname: Zotov
authors.forename: R V
authors.initials: RV
authors.lastname: Liubota
authors.forename: N F
authors.initials: NF
authors.lastname: Anikus'ko
authors.forename: I I
authors.initials: II
authors.lastname: Liubota
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002064:Buserelin / Q000627:therapeutic use; D005260:Female; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008875:Middle Aged; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism; D047648:Perimenopause; D017697:Premenopause; D016019:Survival Analysis; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D017273:Goserelin; D016729:Leuprolide; D002064:Buserelin